US FDA Puts Gilead Sciences Blood Cancer Drug Studies on Hold
[ad_1]
(Reuters) -Gilead Sciences stated on Monday the U.S. well being regulator positioned a medical maintain on research of its blood most cancers drug, only a month after the corporate scrapped a late-stage trial as a result of efficacy considerations.
The corporate gained entry to the drug, magrolimab, with its $4.9 billion buyout of Forty Seven Inc in March 2020.
The corporate stated the U.S. Meals and Drug Administration (FDA) had paused screening and enrollment of latest research contributors, whereas the sufferers already below the research might proceed to obtain remedy.
Research of magrolimab in strong tumors additionally to proceed with none affect from the FDA motion, stated the corporate.
The corporate was finding out the drug together with a sort of chemotherapy referred to as azacitidine for the remedy of sufferers with a better threat of myelodysplastic syndromes — a uncommon group of bone marrow failure issues.
(Reporting by Khushi Mandowara in Bengaluru; Modifying by Shilpi Majumdar)
Copyright 2023 Thomson Reuters.
[ad_2]
Source link
